There were 2,295 press releases posted in the last 24 hours and 360,096 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image